Schernthaner, G., Shehadeh, N., Ametov, A. S., Bazarova, A. V., Ebrahimi, F., Fasching, P., . . . Visockienė, Ž. (2020). Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc Diabetol.
Chicago Style CitationSchernthaner, Guntram, et al. "Worldwide Inertia to the Use of Cardiorenal Protective Glucose-lowering Drugs (SGLT2i and GLP-1 RA) in High-risk Patients With Type 2 Diabetes." Cardiovasc Diabetol 2020.
MLA CitationSchernthaner, Guntram, et al. "Worldwide Inertia to the Use of Cardiorenal Protective Glucose-lowering Drugs (SGLT2i and GLP-1 RA) in High-risk Patients With Type 2 Diabetes." Cardiovasc Diabetol 2020.
Warning: These citations may not always be 100% accurate.